Phase II study of bevacizumab, cisplatin, and docetaxel plus maintenance bevacizumab as first-line treatment for patients with advanced non-squamous non-small-cell lung cancer combined with exploratory analysis of circulating endothelial cells: Thoracic Oncology Research Group (TORG)1016

BACKGROUND: Preclinical studies have demonstrated that docetaxel and bevacizumab may act synergistically by decreasing endothelial cell proliferation and preventing circulating endothelial progenitor mobilization. The objective of this study was to assess the efficacy and safety of a combination the...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :BMC Cancer
Главные авторы: Ikeda, Satoshi, Kato, Terufumi, Ogura, Takashi, Sekine, Akimasa, Oda, Tsuneyuki, Masuda, Noriyuki, Igawa, Satoshi, Katono, Ken, Otani, Sakiko, Yamada, Kouzo, Saito, Haruhiro, Kondo, Tetsuro, Hosomi, Yukio, Nakahara, Yoshiro, Nishikawa, Masanori, Utumi, Keiko, Misumi, Yuki, Yamanaka, Takeharu, Sakamaki, Kentaro, Okamoto, Hiroaki
Формат: Artigo
Язык:Inglês
Опубликовано: BioMed Central 2018
Предметы:
Research Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC5833040/
https://ncbi.nlm.nih.gov/pubmed/29499653
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-018-4150-y
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы